Celularity Inc. Class A Common Stock (CELU)

Price$0.87

Value ScoreB

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-64.31%

Price vs S&P 500 (4W)-0.85%

VGM Score37.98

Market Capitalization$25.25M

All Metrics

Book Value / Share (Quarterly)$0.39

P/TBV (Annual)1.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.88%

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)-29.57%

Gross Margin (TTM)24.39%

Net Profit Margin (TTM)-345.45%

EPS (TTM)$-3.59

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-3.59

EPS (Annual)$-3.58

ROI (Annual)-113.87%

Gross Margin (Annual)24.39%

Net Profit Margin (5Y Avg)-340.92%

Cash / Share (Quarterly)$0.21

Revenue Growth QoQ (YoY)-77.37%

ROA (Last FY)-43.53%

Revenue Growth TTM (YoY)-51.03%

EBITD / Share (TTM)$-2.79

ROE (5Y Avg)-245.63%

Operating Margin (TTM)-274.53%

Cash Flow / Share (Annual)$-0.35

P/B Ratio2.86x

P/B Ratio (Quarterly)5.29x

Net Income / Employee (Annual)$-745,700

EV / Revenue (TTM)2.52x

Net Interest Coverage (TTM)-13.27x

ROA (TTM)-77.94%

EV / EBITDA (TTM)4.44x

EPS Incl Extra (Annual)$-3.58

Current Ratio (Annual)0.39x

Quick Ratio (Quarterly)0.14x

3-Month Avg Trading Volume0.17M

52-Week Price Return-54.57%

EV / Free Cash Flow (Annual)3.50x

Revenue / Employee (TTM)$215,900

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)0.95x

Asset Turnover (Annual)0.41x

52-Week High$4.35

Operating Margin (5Y Avg)-370.10%

EPS Excl Extra (Annual)$-3.58

26-Week Price Return-56.38%

Quick Ratio (Annual)0.28x

13-Week Price Return-27.31%

Total Debt / Equity (Annual)4.75x

Current Ratio (Quarterly)0.15x

Enterprise Value$66.89M

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-57.40%

Revenue / Employee (Annual)$215,900

Inventory Turnover (Annual)2.69x

Pretax Margin (Annual)-345.44%

Cash / Share (Annual)$0.03

3-Month Return Std Dev71.17%

Gross Margin (5Y Avg)34.35%

Net Income / Employee (TTM)$-745,700

ROE (Last FY)-654.89%

Net Interest Coverage (Annual)-13.27x

EPS Basic Excl Extra (Annual)$-3.58

Receivables Turnover (TTM)2.92x

Total Debt / Equity (Quarterly)4.79x

EPS Incl Extra (TTM)$-3.59

Receivables Turnover (Annual)2.57x

ROI (TTM)-92.04%

P/S Ratio (TTM)0.95x

Pretax Margin (5Y Avg)-340.87%

Revenue / Share (Annual)$1.04

Tangible BV / Share (Annual)$1.58

Price vs S&P 500 (52W)-78.93%

Year-to-Date Return-21.41%

5-Day Price Return-18.48%

EPS Normalized (Annual)$-3.58

ROA (5Y Avg)-40.28%

Net Profit Margin (Annual)-345.45%

Month-to-Date Return-13.63%

Cash Flow / Share (TTM)$-0.44

EBITD / Share (Annual)$-2.79

Operating Margin (Annual)-274.53%

ROI (5Y Avg)-86.18%

LT Debt / Equity (Quarterly)4.07x

EPS Basic Excl Extra (TTM)$-3.59

P/TBV (Quarterly)8.85x

P/B Ratio (Annual)5.20x

Inventory Turnover (TTM)6.71x

Pretax Margin (TTM)-345.44%

Book Value / Share (Annual)$0.39

Price vs S&P 500 (13W)-35.56%

Beta0.56x

Revenue / Share (TTM)$0.93

ROE (TTM)-272.44%

52-Week Low$0.71

vGradeB

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q4 25-0.85est. -1.53

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CELUCelularity Inc. Class A Common Stock	B	F	D	$0.87
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Celularity is a clinical-stage biotechnology company developing placental-derived cell therapies for cancer, immunological, infectious, and degenerative diseases. Its pipeline includes natural killer cells, engineered T cells (including CAR-T), and mesenchymal stromal cells. The company operates three business segments—Cell Therapy, Degenerative Disease, and Bio-banking—with the bio-banking division currently serving as the primary revenue source.